Immune modulation with long range ordered, layered double hydroxides

Patent metadata

Field	Value
Publication number	US-9402897-B2
Application number	US-201113640213-A
Country	US
Kind code	B2
Filing date	Apr 11, 2011
Priority date	Apr 9, 2010
Publication date	Aug 2, 2016
Grant date	Aug 2, 2016

Abstract

The invention provides a long range ordered, layered double hydroxide compound for use in modulating an immune response to an antigen, and an immune modulator composition comprising the layered double hydroxide and an interlayer anion A. The compound is [M II (1-x) M III x (OH) 2 ] x+ [A n- x/n ], in which M II is a divalent metal cation or a mixture of two or more divalent metal cations, M III is a trivalent metal cation or a mixture of two or more trivalent meta cations, or a mixture of one or more trivalent metal cation with one or more quadravalent metal cation, x is from 2:1 to 1:4, and A is an interlayer anion having a charge n, wherein optionally some or all of the interlayer anion A may be replaced by one or biologically active agent and/or one or more antigen, and wherein A is selected from conjugate bases of acids having a pKa of −4 or higher.

First claim

The invention claimed is:

1. A composition comprising
(i) a long range ordered, layered double hydroxide (LDH) of a formula:
[M II (1-x) M III x (OH) 2 ] x+ [A n- x/n ]

in which
M II is a divalent metal cation or a mixture of two or more divalent metal cations,
M III is a trivalent metal cation or a mixture of two or more trivalent metal cations, or a mixture of one or more trivalent metal cation with one or more quadravalent metal cation,
x is such that the ratio of M II to M III is 2:1 or 1:4 and
A is an interlayer anion having a charge n, wherein A is selected from conjugate bases of acids having a pKa of 1 or higher, with the proviso that when M II comprises Ca +2 , A is selected from conjugate bases of acids having a pKa of −4 or higher;
and
(ii) one or more antigens;
wherein the long range ordered, layered double hydroxide compound is not a LDH-hybrid where the anion A has been replaced by a biologically active agent and/or the one or more antigens and/or other antigens.

2. The composition of claim 1 , further comprising dendritic cells in combination therewith.

3. The composition of claim 2 , further comprising T cells in combination with the treated dendritic product.

4. The composition of claim 1 , wherein the layered double hydroxide compound comprises:
long-range cation-ordering; and
a surface pKa that is greater than 5.2.

5. The composition layered double hydroxide compound of claim 1 , wherein the layered double hydroxide compound is a Mg—Al based compound of the formula with x=⅓ and A is CO 3 2− , or HCO 3 − .

6. The composition of claim 1 , wherein the layered double hydroxide compound is a Mg—Al based compound of the formula with x=⅓ and A is CO 3 2− HO—, HOO − , ClO − , or HCO 3 − .

7. The composition of claim 1 , wherein the one or more antigens is selected from: virally-derived antigens; bacterially-derived antigens; fungal-derived antigens, yeast- and mould-derived antigens; protozoa-parasite derived antigens; metazoa-parasite derived antigens; tumour antigens; blood group antigens; antigens from allergens and immunosensitivities; antigens from transplantation; self antigens; and DNA vaccination antigens.

8. The composition of claim 1 , wherein the layered double hydroxide compound is present as a particle having a particle diameter from 200 nm to 750 nm.

9. A composition comprising
(i) a long range ordered, layered double hydroxide (LDH) of a formula
[M II (1-x) M III x (OH) 2 ] x+ [A n- x/n ]

in which M II is Mg, M III is Al, x=⅓, such that the ratio of M II to M III is 2:1, and A is CO 3 2− and
(ii) one or more antigens selected from: virally-derived antigens; bacterially-derived antigens; fungal-derived antigens; yeast- and mould-derived antigens; protozoa-parasite derived antigens; metazoa-parasite derived antigens; tumour antigens; blood group antigens; antigens from allergens and immunosensitivities; antigens from transplantation; self antigens; and DNA vaccination antigens.

Assignees

• Austyn Jonathan M
• O'Hare Dermot M
• Lambrecht Bart
• Isis Innovation
• Univ Gent

Inventors

• Austyn Jonathan M
• O'Hare Dermot M
• Lambrecht Bart

Classifications

• A61P37/00

  Drugs for immunological or allergic disorders · CPC title

• A61P37/08

  Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) · CPC title

• A61P41/00

  Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution · CPC title

• C01P2004/52

  highly monodisperse size distribution · CPC title

• C01P2002/50

  Solid solutions · CPC title